← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Molecular Theranostics, Llc
Beachwood, OH
$4,892,605
Total funding
5
Grants
Funding over time
peak $1.3M · FY2015–24$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,892,605 · 5
By mechanism
R44$4,083,047 · 2
R43$809,558 · 3
Investigators at Molecular Theranostics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.$1,000,342
R44 · FY2017 · CA
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer$1,000,000
R44 · FY2022 · CA
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer$1,000,000
R44 · FY2023 · CA
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.$999,657
R44 · FY2018 · CA
A peptide targeted fluorescence probe for precision surgery of head and neck cancer$294,505
R43 · FY2024 · DE
Development of peptide drug conjugates for cancer therapy$265,179
R43 · FY2023 · CA
Commercialization of targeted MRI contrast agents for prostate cancer imaging.$249,874
R43 · FY2015 · CA
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.$81,598
R44 · FY2019 · CA
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.$1,450
R44 · FY2019 · CA